Albemarle Corporation

step: "01" title: "Business Model & Value Chain" ticker: ALB company: "Albemarle Corporation" source: coverage-next-full created: 2026-05-28

Step 01 — Business Model & Value Chain: Albemarle Corporation (ALB)

Key Findings

• ALB is a vertically integrated lithium + bromine specialty chemicals producer, with ~75–80% of normalized revenue from the Energy Storage (lithium) segment and ~18–20% from Specialties (bromine) [S1][S2].
• The Ketjen refining-catalyst segment (~$1.0–1.1B revenue at peak) was divested in March 2026 for combined proceeds of ~$670M (Ketjen sale to KPS Capital Partners + 50% Eurecat JV stake to Axens) [S3]. Post-divestiture, ALB is a focused 2-segment operator.
• Value chain depth: ALB controls the full lithium chain from resource extraction (Atacama brine, Chile; Greenbushes/Wodgina hard rock, Australia) through conversion (LiOH, Li₂CO₃ at Kemerton, La Negra, China JVs) to specialty compounds for Tier-1 battery OEMs [S2].
• Net signal: mixed. Business is simpler post-Ketjen; the lithium franchise is genuinely world-scale, but exposure to commodity-price cycles is now structurally higher than during the diversified era.

Implications for Thesis and Valuation

ALB's business is best analyzed as two stacked businesses:

1. A high-beta, commodity-price-sensitive lithium franchise (Energy Storage) whose EBITDA can swing from ~$4B (FY2022) to negative (FY2024) on the same asset base.
2. A stable bromine oligopoly (Specialties) generating ~$250–350M of segment EBITDA at mid-cycle, providing a real cash-flow floor.

Valuation must therefore use a sum-of-the-parts lens: a mid-cycle multiple on the lithium franchise plus a stable specialty-chemical multiple on Specialties. A single blended P/E is uninformative through the cycle.

Objective

Map ALB's segments, products, customer base, supply chain, and competitive position to define the analytical framework used throughout the report.

Narrative Analysis

Segment 1 — Energy Storage (lithium): ALB sells lithium hydroxide (LiOH, used in nickel-rich NMC and NCA cathodes for EVs), lithium carbonate (Li₂CO₃, LFP cathodes and consumer electronics), and lithium chloride/specialty grades [S2]. Customers are Tier-1 cell makers (LG Energy Solution, Panasonic, CATL, SK On) and select OEMs (Tesla via direct supply agreements) [S4]. The segment is vertically integrated: ALB owns equity stakes in or operates the resource (Atacama brine in Chile via a 50/50 partnership structure with SQM-style royalty to CORFO; Greenbushes via 49% Talison JV with Tianqi/IGO; Wodgina via 50/50 MARBL JV with Mineral Resources) and the conversion plants (Kemerton, Australia; La Negra, Chile; multiple China JV conversion facilities) [S2][S5]. Pricing has shifted from largely fixed-price multi-year contracts (pre-2022) toward index-linked / variable pricing on ~75–80% of book today, which means full commodity exposure on the upside and downside [S6].

Segment 2 — Specialties (bromine + specialty lithium): Bromine-based flame retardants (electronics housings, automotive plastics), oilfield clear brines (drilling fluids), pharmaceutical intermediates, and specialty lithium grades for grease, polymers, and pharma [S2]. Resource base: Smackover Formation brine in Magnolia, Arkansas and Dead Sea operations [S2]. The bromine market is a 3-player global oligopoly (Albemarle, ICL Group, Jordan Bromine) — pricing has been stable with mid-single-digit annual escalation, and the segment has delivered ~$1.0–1.1B revenue at ~25–30% gross margin through the entire 2020–2025 cycle [S7].

Segment 3 — Ketjen (DIVESTED March 2026): Was the refining-catalysts business (FCC for gasoline, hydroprocessing for cleaner fuels). Sold to KPS Capital Partners (renamed ChemCat) on March 2, 2026 for ~$547M; the 50% Eurecat JV (regeneration services) was sold to Axens in January 2026 for ~$123M; combined ~$670M [S3]. Proceeds were applied to debt reduction (long-term debt fell from $3,194M YE 2025 to $1,882M TTM Q1 2026) [S8].

Value-chain layer map:

Why this matters: ALB's competitive position is resource-position + conversion scale, not branding or switching costs. The downside cycle (2023–2025) demonstrated that customer relationships do not protect realized prices — when LCE spot prices collapsed from ~$80/kg to ~$8–10/kg, ALB's realized prices followed, and gross margins compressed from 42% to 1.2% [S1][S6]. The franchise is real, but its earning power is structurally cyclical unless the company can shift pricing structure (more fixed-price) or unless lithium spot prices stabilize at a higher floor.

Evidence and Sources

• Segment revenue split: Energy Storage $3,800M / Specialties $1,100M / Ketjen ~$240M (thru Nov 2025) of FY2025 $5,143M revenue [S1].
• Ketjen sale: completed March 2, 2026; combined proceeds with Eurecat ~$670M; debt reduction confirmed in Q1 2026 10-Q [S3][S8].
• Pricing mix shift: ALB management commentary in 8-K releases through 2023–2024 confirmed variable/index pricing now dominates the book [S6].
• Bromine stability: Specialties revenue $1,000–1,200M annually 2020–2025; gross margin compression in cyclical lithium did not flow through to Specialties [S7].

Assumption Register Updates

Tables and Calculations

FY2025 Segment Revenue Split

Open Questions and Data Gaps

1. Exact mix of fixed-price vs. variable/index lithium contracts — disclosed only directionally.
2. Per-asset cash production cost (Atacama vs. Greenbushes vs. Kemerton vs. Wodgina) — needed for cost-curve positioning in Step 09/10.
3. Whether bromine pricing power is degrading at the margin (electronics flame-retardant substitution risk).

Source Index

step: "04" title: "Financial Quality & Adversarial Sweep" ticker: ALB company: "Albemarle Corporation" source: coverage-next-full created: 2026-05-28

Step 04 — Financial Quality & Adversarial Sweep: ALB

Key Findings

• GAAP accounting is largely conservative and standard for the industry; revenue recognition follows shipment / delivery, no signs of channel stuffing or revenue acceleration [S1].
• Impairment charges in 2024 ($1.03B) and 2025 ($280M) were appropriate response to lithium price collapse — Kemerton Train 3 and Ketjen pre-sale carrying-value marks [S2]. Conservative impairment posture, not aggressive.
• One material historical concern: FCPA settlement (2023, $103M) related to pre-2010 payments in Vietnam/India/Indonesia. Company self-reported and remediated; independent compliance monitor was imposed [S3]. Risk: governance overhang, not ongoing material loss.
• Net signal: positive on financial quality, with one significant historical compliance scar.

Implications for Thesis and Valuation

Earnings quality through the cycle is better than the headline numbers suggest. The 2024–2025 GAAP losses are heavily weighted by non-cash impairments — underlying operating cash flow remained positive ($702M and $1,282M respectively) even at the bottom of the lithium cycle [S4]. This is critical for a Commodity/Upstream story: ALB demonstrated the ability to generate cash through a 90%+ price collapse, which de-risks the downside scenarios.

The FCPA settlement creates a small but persistent governance risk premium that should be reflected as ~50–100 bps additional cost of equity vs. a clean specialty-chemicals comp.

Objective

Assess earnings quality, accounting choices, restatements, and conduct the mandatory Adversarial Research Sweep (short reports, investigations, lawsuits, governance concerns).

Narrative Analysis

Earnings quality scorecard:

Restatements / audit issues: None material in 2020–2025 period [S1]. Auditor: PricewaterhouseCoopers (continuing engagement).

Adversarial Research Sweep:

Detailed FCPA notes: The 2023 settlement related to payments made by intermediaries / agents to government officials in Vietnam, India, and Indonesia before 2010. Albemarle self-disclosed to DOJ in 2017–2018 and cooperated through investigation. The settlement included a deferred prosecution agreement (DPA), $103M in disgorgement + penalty, and a 2-year independent compliance monitorship (extending into 2026) [S3]. There is no evidence of repeat misconduct post-2010; the FCPA matter is contained, but creates ongoing reputational and regulatory monitoring overhead.

Non-GAAP usage: Albemarle reports adjusted EBITDA and adjusted EPS that exclude impairments, acquisition/divestiture-related items, and certain restructuring charges. The adjustments are clearly disclosed in earnings releases, and the magnitude of adjustments in 2024–2025 is large but documented [S10]. We will use adjusted EBITDA for cyclical comparison and GAAP net income for fundamental valuation.

Evidence and Sources

• OCF positive every year 2020–2025 even with GAAP losses — see xbrl_summary.md cash flow [S4].
• FCPA settlement $103M (2023) — public DOJ/SEC announcements [S3].
• Capex < D&A in 2025 ($590M vs. $659M) — discipline visible [S4].

Assumption Register Updates

Tables and Calculations

Earnings quality snapshot:

The OCF-NI gap in 2024–2025 is almost entirely impairment-driven. Adjusted net income shows a much smaller actual loss footprint.

Open Questions and Data Gaps

1. Status of any FCPA-related residual obligations after monitorship ends (likely 2026).
2. Inventory carrying-value reserves at YE 2025 (vs. potential additional writedowns if lithium prices weaken again).
3. Class action status updates beyond initial complaints.

Source Index